Gustaf Salford, CEO of Elekta, said: “Elekta has set an ambitious roadmap for reducing emissions in line with the Paris Agreement and aligning our operations with climate science. Sustainability is fundamental to our strategy and this validation by SBTi confirms that we’re on track to minimizing our environmental footprint while maximizing social value.”

Hilma Nordquist, Elekta’s Group Sustainability Director, added: “One of our targets is to reduce greenhouse gas emissions per cancer treatment course* delivered with Elekta’s products. This target was chosen to decrease the environmental footprint of Elekta’s activity within the context of a growing cancer burden that will require more treatments. By tracking emissions per cancer treatment course, we promote more environmentally efficient solutions to treat cancer globally in order to tackle the increase in cases. This goal supports our journey for a more sustainable future.”

The Intergovernmental Panel on Climate Change has clearly warned that the world faces unavoidable multiple climate hazards over the next two decades due to the impact of global warming and climate change. Elekta is striving to support the necessary green transition through, among other actions, its science-based targets such as:
 
For Scope 1(1) (including direct emissions from Elekta’s own operations) and Scope 2(2) (including indirect emissions from purchased electricity and district heating), Elekta shall reduce absolute emissions by 46.2 percent by end of fiscal year 2031/32.
 
For Scope 2 (including indirect emissions from purchased electricity and district heating) Elekta shall transition to 100 percent renewable electricity by end of 2030.
 
In Scope 3(3) (including indirect emissions occurring across our value chain) Elekta has two targets, one involving the use of our products and one involving suppliers:

• Use of products: Emissions from the use and end-of-life processing of Elekta’s products shall be reduced by 55 percent per radiotherapy treatment course by end of fiscal year 2031/32.

• Suppliers: Elekta shall engage a proportion of suppliers to have science-based targets by the end of fiscal year 2026/27. The target proportion corresponds to 27.5 percent of emissions from suppliers. 

 (1), (2) Scope 1 (direct emissions) and Scope 2 (indirect emissions from purchased energy) cover emissions across the company’s operations.
(3) Scope 3 refers to indirect value chain emissions.
 
*A radiotherapy treatment course is defined as a full radiotherapy treatment for an individual, which can consist of one or more treatment sessions. 
 
Read more about how Elekta is actively committed to global sustainability at https://www.elekta.com/company/sustainability/
Read more about Science Based Targets initiative

# # #
 
For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com 
Time zone: CET: Central European Time
 
Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time
 
About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.